Hepatocellular carcinoma
Therapeutic area
Oncology
Rare disease
Yes
- Definition
- A malignant tumor that arises from hepatocytes. Hepatocellular carcinoma is relatively rare in the United States but very common in all African countries south of the Sahara and in Southeast Asia. Most cases are seen in patients over the age of 50 years, but this tumor can also occur in younger individuals and even in children. Hepatocellular carcinoma is more common in males than females and is associated with hepatitis B, hepatitis C, chronic alcohol abuse and cirrhosis. Serum elevation of alpha-fetoprotein occurs in a large percentage of patients with hepatocellular carcinoma. Grossly, hepatocellular carcinoma may present as a single mass, as multiple nodules, or as diffuse liver involvement. Microscopically, there is a wide range of differentiation from tumor to tumor (well differentiated to poorly differentiated tumors). Hepatocellular carcinomas quickly metastasize to regional lymph nodes and lung. The overall median survival of untreated liver cell carcinoma is about 4 months. The most effective treatment of hepatocellular carcinoma is complete resection of the tumor. Lately, an increasing number of tumors have been treated with liver transplantation.
- Genetic basis
- Yes
- Non-human condition
- No
- Rare disease
- Yes
- Listing at source
- Listed
- Condition name
- Hepatocellular carcinoma
- Therapeutic area
- Oncology
- hepatocellular carcinoma
- HCC
- cancer, hepatocellular
- carcinoma of liver
- carcinoma of liver cells
- carcinoma of the liver cells
- carcinoma, hepatocellular, malignant
- hepatoblastoma, somatic
- hepatocellular adenocarcinoma
- hepatocellular cancer
- hepatocellular cancer, somatic
- hepatocellular carcinoma
- hepatocellular carcinoma, childhood type, somatic
- hepatocellular carcinoma, somatic
- hepatoma
- liver carcinoma
- liver cell cancer (hepatocellular carcinoma)
- liver cell carcinoma
- primary carcinoma of liver cells
- primary carcinoma of the liver cells
- adult hepatoma
- adult primary hepatocellular carcinoma
- Severity
- Severe
- Endocrinology
- Gastroenterology
- Oncology
- MONDO ID
- MONDO:0007256
- Parent condition
- MONDO:0004970
Related records
Broader conditions (25)
- Adenocarcinoma
- Cancer
- Cancer or benign tumor
- Carcinoma
- Carcinoma of liver and intrahepatic biliary tract
- Digestive system cancer
- Digestive system carcinoma
- Digestive system disorder
- Digestive system neoplasm
- Disease
- Disease by body system or component
- Disease by etiologic mechanism
- Endocrine gland neoplasm
- Endocrine system disorder
- Epithelial neoplasm
- Glandular cell neoplasm
- Hepatobiliary disorder
- Hepatobiliary neoplasm
- Human disease
- Liver and intrahepatic bile duct neoplasm
Narrower conditions (11)
- Adult hepatocellular carcinoma
- Aflatoxin-related hepatocellular carcinoma
- Fibrolamellar hepatocellular carcinoma
- Hepatoblastoma
- Hepatocellular clear cell carcinoma
- Liver diffuse large B-cell lymphoma
- Macrotrabecular hepatoblastoma
- Mixed fibrolamellar hepatocellular carcinoma
- Mixed hepatoblastoma
- Pediatric hepatocellular carcinoma
- Sclerosing hepatic carcinoma
Trials (3,658)
- "cindilizumab + Bevacizumab + Coenzyme I for Injection" in Unresectable Hepatocellular Carcinoma
- "Cocktail" Therapy for Hepatitis B Related Hepatocellular Carcinoma
- "Double Low-Dose" DECT for HCC Imaging
- [18F]FMISO PET/CT After Transcatheter Arterial Embolization in Imaging Tumors in Patients With Liver Cancer
- [68Ga]DOTATATE-PET/MRI in Hepatocellular Carcinoma
- [68Ga]Ga-PSMA PET/CT in Hepatocellular Carcinoma: Impact of Multiparametric Dynamic Whole-body Imaging and Kinetic Modeling.
- 11C-acetate for Treatment Response After Radiotherapy for HCC
- 11C-Acetate PET/CT Non-FDG-Avid Tumors
- 11C-Choline PET/CT and DWI MRI for Response Assessment of HCC Candidate to TARE
- 15 vs 45 Minute Pringle Maneuver in Liver Cancer Resection: Randomized Noninferiority Trial
- 188RE-SSS Lipiodol to Treat HepatoCellular Carcinomas
- 18F-DCFPyL PET/CT in Hepatocellular Carcinoma
- 18F-FDG PET in HCC Patients Candidate to Treatment With Sorafenib
- 18F-FDGal PET/CT and PET/MRI in Patients With Hepatocellular Carcinoma
- 18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
- 18F-FluoroethylCholine Positron Emission Tomography: a Promising Diagnostic Tool for Hepatocellular Carcinoma
- 18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant
- 18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors
- 24hr Imaging Of HCC After EOVIST
- 29-Gene Liver Cancer Subtype and Immunotherapy Effectiveness
Approved drugs (3)
- Cabozantinib S-malate
- Sorafenib tosylate
- Tremelimumab
Drugs in development (312)
- .ALPHA.-pyrrolidinononanophenone Phase 1
- [18F]FLUOROMISONIDAZOLE Early phase 1
- ABC-294640 Phase 2
- Abemaciclib Phase 2
- ABX-196 Phase 1
- Acetazolamide Phase 3
- Acetic acid C-11 Phase 2
- Adagloxad simolenin Phase 2
- Adakitug Phase 2
- Adebrelimab Phase 2
- Aglatimagene besadenovec Phase 3
- Albumin human Phase 3
- Aldesleukin Phase 1
- Aldoxorubicin hydrochloride Phase 1
- Alectinib Phase 1
- Amcasertib Phase 2
- Amivantamab Phase 2
- Amsilarotene Phase 2
- Aprepitant Phase 3
- Arginine Phase 3
Other linked drugs (8)
- Adefovir dipivoxil
- Alcohol
- Carvedilol
- Interferon alfa-N3
- OBI-3424
- ORIC-101
- Parecoxib sodium
- Pregabalin